Cargando…

Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes

BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is an effective oral antidiabetic agent as both monotherapy and when combined with insulin. Data from three observational studies performed in patients with type 2 diabetes receiving sitagliptin therapy in the routine clinical setting were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuasa, Shouhei, Sato, Kazuyoshi, Takai, Masahiko, Ishikawa, Masashi, Umezawa, Shinichi, Kubota, Akira, Maeda, Hajime, Kanamori, Akira, Miyakawa, Masaaki, Tanaka, Yasushi, Terauchi, Yasuo, Matsuba, Ikuro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852779/ https://www.ncbi.nlm.nih.gov/pubmed/27222674 http://dx.doi.org/10.14740/jocmr2540w

Ejemplares similares

A Study of Seasonal Variation in the Effect of Add-On Sitagliptin on Blood Glucose Control in Insulin-Treated Patients With Type 2 Diabetes
por: Takai, Masahiko, et al.
Publicado: (2020)

Primary Care-Based Investigation of the Effect of Sitagliptin on Blood Pressure in Hypertensive Patients With Type 2 Diabetes
por: Yuasa, Shouhei, et al.
Publicado: (2017)

Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study
por: Takai, Masahiko, et al.
Publicado: (2019)

Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study
por: Ishikawa, Masashi, et al.
Publicado: (2015)

Factors Associated With Reduced Efficacy of Sitagliptin Therapy: Analysis of 93 Patients With Type 2 Diabetes Treated for 1.5 Years or Longer
por: Kanamori, Akira, et al.
Publicado: (2013)

Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients
por: Kubota, Akira, et al.
Publicado: (2012)

Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study
por: Umezawa, Shinichi, et al.
Publicado: (2015)

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
por: Kubota, Akira, et al.
Publicado: (2012)

Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study
por: Iemitsu, Kotaro, et al.
Publicado: (2016)

Is a Switch From Insulin Therapy to Liraglutide Possible in Japanese Type 2 Diabetes Mellitus Patients?
por: Kawata, Takehiro, et al.
Publicado: (2014)

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea
por: Kubota, Akira, et al.
Publicado: (2014)

Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study
por: Iemitsu, Kotaro, et al.
Publicado: (2017)

Present status of insulin therapy for type 2 diabetes treated by general practitioners and diabetes specialists in Japan: Third report of a cross‐sectional survey of 15,652 patients
por: Arai, Keiko, et al.
Publicado: (2012)

Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study
por: Matsuba, Ikuro, et al.
Publicado: (2020)

Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus
por: Kubota, Akira, et al.
Publicado: (2011)

Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study
por: Iizuka, Takashi, et al.
Publicado: (2016)

Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study
por: Iizuka, Takashi, et al.
Publicado: (2016)

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus
por: Kawata, Takehiro, et al.
Publicado: (2017)

Cross‐sectional survey of diabetic neuropathy in Kanagawa and clinical significance of a touch test using tissue paper
por: Jin, Yasuyuki, et al.
Publicado: (2012)

The Proportion of Long-term Response to Anti-N IgG Antibody after 12 Months for COVID-19 Subclinical Infections and a Longitudinal Survey for COVID-19 Subclinical Infections in 2021
por: Matsuba, Ikuro, et al.
Publicado: (2022)

Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus
por: Takeda, Hiroshi, et al.
Publicado: (2019)

Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study
por: Takeda, Hiroshi, et al.
Publicado: (2016)

Multinational Observational Study to Understand Insulin Treatment Intensification: Japanese Subgroup Analysis of the MOSAIc Study
por: Matsuba, Ikuro, et al.
Publicado: (2022)

Effect of Caloric Intake 25 or 30 kcal/kg/day on the Glycemic Control in Obese Patients With Type 2 Diabetes
por: Masuda, Kiyomi, et al.
Publicado: (2013)

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Shigematsu, Erina, et al.
Publicado: (2014)

A survey of clinical physician's perceptions of stigma and advocacy in patients with type 2 diabetes in Kanagawa, Japan
por: Matsuzawa, Yoko, et al.
Publicado: (2022)

Fasting Insulin Levels and Metabolic Risk Factors in Type 2 Diabetic Patients at the First Visit in Japan: A 10-year, nationwide, observational study (JDDM 28)
por: Matsuba, Ikuro, et al.
Publicado: (2012)

Study on Continuation of Antibody Prevalence Six Months after Detection of Subclinical Severe Acute Respiratory Syndrome Coronavirus 2 Infections
por: Matsuba, Ikuro, et al.
Publicado: (2021)

The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
por: Kobayashi, Kazuo, et al.
Publicado: (2021)

Comparison of questionnaire responses regarding awareness of Japanese Society of Hypertension guidelines for the management of hypertension between 2014 and 2019 in primary care
por: Kobayashi, Kazuo, et al.
Publicado: (2021)

Tofogliflozin decreases body fat mass and improves peripheral insulin resistance
por: Matsuba, Ren, et al.
Publicado: (2018)

Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists
por: Kobayashi, Kazuo, et al.
Publicado: (2022)

Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin
por: Chung, Hye Soo, et al.
Publicado: (2014)

Sodium–glucose cotransporter 2 inhibitor‐induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score‐matched model analysis in Japan
por: Kobayashi, Kazuo, et al.
Publicado: (2021)

Concomitant treatment with insulin and sodium–glucose cotransporter 2 inhibitors was associated with the renal composite outcome in Japanese patients with type 2 diabetes and chronic kidney disease: A propensity score‐matched analysis
por: Toyoda, Masao, et al.
Publicado: (2022)

Cross-National Variation in Glycemic Control and Diabetes-Related Distress Among East Asian Patients Using Insulin: Results from the MOSAIc Study
por: Matsuba, Ikuro, et al.
Publicado: (2016)

A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes
por: Shigematsu, Erina, et al.
Publicado: (2017)

Polypharmacy influences the renal composite outcome in patients treated with sodium‐glucose cotransporter 2 inhibitors
por: Kobayashi, Kazuo, et al.
Publicado: (2022)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Survey of the current status of subclinical coronavirus disease 2019 (COVID-19)
por: Matsuba, Ikuro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a8gjrmg090r6u9c6ecque3mn96